Avelumab Exposure and Merkel Cell Carcinoma: A Review of Causation Evidence

From General Health to Specific Exposure Concerns

The legacy of general health and science information has long provided a foundational framework for understanding broad biological principles and risk factors across populations. Within this heritage, the emphasis on preventive medicine and environmental influences has shaped public awareness of how external agents can interact with human physiology. As this knowledge base evolved, it became increasingly clear that specific exposures in controlled settings—such as clinical or occupational environments—warrant focused scrutiny. The transition from general health contexts to more specialized domains involves recognizing that certain therapeutic or industrial agents, initially developed for beneficial purposes, may carry unintended consequences under particular conditions of use. This pivot requires a careful examination of exposure pathways, dose-response relationships, and population susceptibility, moving beyond population-level correlations to individual-level risk assessment. In the case of avelumab, a monoclonal antibody employed in oncology, its introduction into clinical practice has prompted investigation into potential links with adverse outcomes, including the development of Merkel cell carcinoma. The concern shifts from general health maintenance to the specific occupational and therapeutic exposure scenarios where healthcare workers, patients, and manufacturing personnel may encounter this agent. Thus, the legacy of general health information now converges with a targeted inquiry into whether avelumab exposure constitutes a causal factor in Merkel cell carcinoma, demanding rigorous evaluation of exposure circumstances and biological plausibility without premature mechanistic assertions.

Avelumab: Mechanism and Approved Use

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The clinical presentation of Merkel cell carcinoma typically involves a rapidly growing, painless, firm, dome-shaped nodule on sun-exposed skin, often in older or immunocompromised individuals. Diagnosis is confirmed by histopathology and immunohistochemistry, showing neuroendocrine differentiation. Approximately 80% of MCC cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The standard treatment for metastatic MCC is the use of anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which show better overall response rates and longer duration of responses compared with conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385/). However, about 50% of patients do not respond or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Evaluating the Causal Link: Avelumab as Treatment, Not Cause

The question of whether avelumab exposure can cause Merkel cell carcinoma is not supported by the available evidence. Instead, avelumab is a treatment for existing MCC. The evidence indicates that avelumab is used to treat metastatic MCC, and its mechanism of action—blocking PD-L1 to enhance T-cell responses—is intended to combat the cancer, not induce it. The reported adverse effects of avelumab include immune-related adverse events such as hypercalcaemia due to reactivation of sarcoidosis, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). There is no evidence in the provided snippets linking avelumab exposure to the development of MCC. Rather, the evidence describes avelumab as a therapeutic agent for MCC, and studies focus on its efficacy and safety in patients already diagnosed with the disease. In terms of mechanistic pathways, avelumab's role as an immune checkpoint inhibitor could theoretically lead to immune overactivation, but this is associated with irAEs, not with causing MCC. The evidence does not describe any pathway by which avelumab would initiate or promote MCC carcinogenesis. The risk context for patients is that avelumab is a treatment option for metastatic MCC, and its use is associated with potential irAEs, but not with causing the cancer itself. The timeline between exposure and health outcomes in the evidence shows that avelumab is administered after MCC diagnosis, and outcomes such as response rates or irAEs are measured during treatment. For example, in the JAVELIN Merkel 200 trial, responses were observed in patients with chemotherapy-refractory MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). In avelumab-refractory patients, subsequent treatment with ipilimumab plus nivolumab showed responses in three out of five patients (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another study reported response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). For affected patients, the clinical interpretation is that avelumab is a standard therapy for metastatic MCC, and its use is not associated with causing the disease. The safety communication context should emphasize that avelumab is approved for treating MCC, and any adverse effects are related to immune activation, not to carcinogenesis. The evidence does not support a causal link between avelumab exposure and the development of Merkel cell carcinoma. Instead, the evidence consistently positions avelumab as a treatment for MCC, with no reported cases of avelumab causing MCC. Therefore, in a causation-focused clinical interpretation, avelumab exposure is not a risk factor for developing MCC; rather, it is a therapeutic intervention for patients who already have the disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

No, the available evidence does not support that avelumab causes Merkel cell carcinoma. Avelumab is an immune checkpoint inhibitor used to treat metastatic Merkel cell carcinoma, and its mechanism of action is designed to fight the cancer, not induce it. Studies consistently show avelumab as a therapeutic agent for existing MCC, with no reported cases of it causing the disease.

What is the evidence for avelumab's role in Merkel cell carcinoma?

Avelumab is approved for treating metastatic Merkel cell carcinoma based on the JAVELIN Merkel 200 trial, which showed objective responses in about one-third of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). The evidence focuses on its efficacy and safety in patients already diagnosed with MCC, and there is no evidence linking avelumab exposure to the development of MCC.

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.